Cipla has achieved a significant milestone with the U.S. Food and Drug Administration (USFDA) granting approval for its Abbreviated New Drug Application (ANDA) for the generic version of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder). The approval covers all three strengths—100/50 mcg, 250/50 mcg, and 500/50 mcg—and allows Cipla to market a therapeutically equivalent alternative to one of the most widely prescribed inhaled combination therapies for asthma and chronic obstructive pulmonary disease (COPD).
On October 8, 2025, the World Health Organization (WHO) released updated guidelines within its consolidated framework on tuberculosis (TB), specifically Module 6: Tuberculosis and Comorbidities, focusing on the critical intersection of TB and undernutrition. Published as part of the WHO’s End TB Strategy, these guidelines address undernutrition as a major global driver of TB, increasing disease susceptibility, worsening treatment outcomes, and contributing to preventable mortality. The recommendations advocate for a people-centered, comprehensive approach to TB care by integrating nutritional interventions to break the cycle of disease and poverty.
This research examines the effect of different glucose-lowering drugs on the risk of exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D) and active COPD. With the assistance of three large U.S.
This systematic review and meta-analysis investigated the effectiveness of triple therapy combinations for treating uncontrolled asthma in adults, with a particular focus on comparing a single inhaler containing beclometasone, formoterol, and glycopyrronium (BDP/FOR/GLY) against other triple therapy options.
